MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPKα

Figure 1

miR-137-3p agomir improves HFD-induced NAFLD in mice. (a) Mice were fed with a HFD for 24 weeks to establish NAFLD, whereas the matched mice were maintained on a ND. Relative miR-137-3p level in the liver from mice was detected (). (b) Primary hepatocytes were isolated from 8 week-year-old C57BL/6 mice and stimulated with 0.5 mmol/L palmitic acid plus 1.0 mmol/L oleic acid (PO) for 24 h. Relative miR-137-3p level in PO-stimulated primary hepatocytes was detected (). (c) For miR-137-3p overexpression, mice were intraperitoneally injected with the miR-137-3p agomir or agomir control (100 mg/kg weekly) for 6 consecutive weeks before being sacrificed. Relative miR-137-3p level in the liver from mice with or without miR-137-3p agomir injection (). (d) Body weight in mice after 24 weeks of HFD feeding (). (e) The weights of epididymal and inguinal fat pad in mice after 24 weeks of HFD feeding (). (f) Food intake (). (g, h) Serum parameters of FBG and insulin in mice (). (i) Quantification of the insulin resistance index HOMA-IR (). (j) Serum parameters of TG and TC in mice (). (k, l) Hepatic lipid accumulation as determined by the TG, TC, and NEFA levels (). (m) Quantification of the liver weight (LW) and LW to tibial length ratio (LW/TL) (). (n) Hepatic hydroxyproline level (). (o) Relative mRNA levels of Col1α1, Col3α1, CTGF, and TGF-β1 in the liver (). (p) Serum ALT and AST levels (). Data were expressed as the , and was considered significant. n.s. indicated no significance.